Trial Profile
A Phase III, Randomised, Double-Blind, Multi-centre, Withdrawal Study Comparing MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphataemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Colestilan (Primary) ; Phosphate binding modulators
- Indications Hyperphosphataemia
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 31 Mar 2014 New trial record
- 11 Dec 2009
- 05 Aug 2009